NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Compliance Implementation Services

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Hire Brings Extensive Pharmaceutical Government Programs Expertise - Compliance Implementation Services (CIS), a pharmaceutical compliance consulting firm is pleased to announce the addition of new management team member, Bill Baxter
New Hire Brings Extensive Pharmaceutical Government Programs Expertise

 

NewswireTODAY - /newswire/ - Philadelphia, PA, United States, 2009/03/30 - Compliance Implementation Services (CIS), a pharmaceutical compliance consulting firm is pleased to announce the addition of new management team member, Bill Baxter.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

CIS is excited to have Mr. Baxter, a proven professional who will help guide the company’s continued growth, specifically in the Government Programs area.

Bill Baxter has over 38 years diverse pharmaceutical industry experience including Medicaid Contracting, Government Affairs, Sales, Sales Management, and Training. Prior to his work at Johnson & Johnson, he taught social studies in the St. Louis School System.

“Many in the industry know Bill’s work with the numerous federal and state programs and his vast experience and knowledge in the Medicaid market,” said Chris Cobourn, VP Regulatory Compliance and Practice Lead.

“His expertise will be a valuable asset to CIS. This is especially true now with so many changes and increased scrutiny at both the Federal and State levels. Bill has been involved in Medicaid and other programs since their beginning. His well rounded understanding of the programs, including the agencies, the regulations, and the operational and organizational impact at the manufacturer, brings a unique perspective that will be a great compliment to our current staff of GP consultants, and we are very excited to have him join the CIS family.”

Bill formerly held the position of Chairman of State Health Care Policy Council, an organization tasked with providing a forum for J&J operating company management to review emerging health care issues and developing policy. He was also a participating member of J&J Medicaid and Medicare Task Forces.

About CIS
CIS (cis-partners.com) is a pharmaceutical compliance consulting firm specializing in establishing a "Culture of Compliance" by providing a deep understanding of industry laws and regulations, innovative and practical approaches and fit-for-purpose solutions. CIS consultants understand and specialize in interpreting and implementing legal and regulatory requirements that have the greatest impact on research, development and commercial activities. This allows clients to proactively manage risk through identification and integration of appropriate compliance strategies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Compliance Implementation Services

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Hire Brings Extensive Pharmaceutical Government Programs Expertise

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Jackie O'Connor - CIS-Partners.com 
484-445-7200 jacquelineoconnor[.]cis-partners.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Compliance Implementation Services securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Compliance Implementation Services / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)